Intravenous immunoglobulin for inflammatory demyelinating polyneuropathy

Authors: Talaei, M; Robertson, NP

Affiliations: Department of Neurology, University Hospital of Wales, Heath Park, Cardiff, CF14 4XN, UK; Division of Psychological Medicine and Clinical Neuroscience, Department of Neurology, University Hospital of Wales, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK.

Publication: Journal of neurology; 2022; 269. 534–536

Abstract: Intravenous immunoglobulin (IVIg) plays a key role in treatment of inflammatory demyelinating polyneuropathies such as Guillain–Barre syndrome (GBS). However, individual response to treatment can be unpredictable, and for those most severely affected, a second dose of IVIg (SIV) is commonly administered despite limited evidence for efficacy. In this month’s journal club, we review two studies which explore the efficacy of second dosing and a third study exploring neurophysiological factors predicting relapse in chronic inflammatory polyneuropathy.